Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Lisbeth V. Jacobsen"'
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9f46c39f4e81dd129c36be39b13296
https://doi.org/10.1007/s40262-016-0410-7
https://doi.org/10.1007/s40262-016-0410-7
Autor:
Rune Viig Overgaard, Lisbeth V. Jacobsen, Christine B. Jensen, John P.H. Wilding, C. W. le Roux
Publikováno v:
Diabetes, Obesity & Metabolism
Aims Liraglutide 3.0 mg, an acylated GLP-1 analogue approved for weight management, lowers body weight through decreased energy intake. We conducted exposure-response analyses to provide important information on individual responses to given drug dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b923028bfb0a741bc00e841bbd4895
https://doi.org/10.1111/dom.12639
https://doi.org/10.1111/dom.12639
Publikováno v:
Clinical Pharmacokinetics
Liraglutide is an acylated glucagon-like peptide-1 analogue with 97 % amino acid homology with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the treatment of type 2 diabetes mellitus, and administered by subcutan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dc0c8bfacde26cbbc3ef80987792a77
https://doi.org/10.1007/s40262-015-0343-6
https://doi.org/10.1007/s40262-015-0343-6
Autor:
Paula M Hale, Silva A. Arslanian, Tadej Battelino, Lisbeth V. Jacobsen, D J Chatterjee, David J. Klein
Publikováno v:
Diabetes Technology & Therapeutics. 16:679-687
The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics, and pharmacodynamics of liraglutide once daily in youth (10-17 years old) with T2D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd69cb2e53ab9c26c37f975166738f94
https://doi.org/10.1089/dia.2013.0366
https://doi.org/10.1089/dia.2013.0366
Autor:
K Kapitzke, Thomas Danne, Torben Biester, Lisbeth V. Jacobsen, Kristin C. Carlsson Petri, Olga Kordonouri, Paula M Hale, Sanja Hald Jacobsen
Publikováno v:
The Journal of pediatrics. 181
Objectives To investigate the safety, tolerability, and pharmacokinetics of liraglutide in adolescents with obesity. Study design This was a randomized, double-blind, placebo-controlled trial. Twenty-one subjects, aged 12-17 years and Tanner stage 2-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f04e233a2ac9e8a8ce435091747d477
https://pubmed.ncbi.nlm.nih.gov/27979579
https://pubmed.ncbi.nlm.nih.gov/27979579
Publikováno v:
The Journal of Clinical Pharmacology. 51:1696-1703
Liraglutide is a once-daily human GLP-1 analog for treatment of type 2 diabetes. Like other GLP-1 analogs, liraglutide delays gastric emptying, which could potentially affect absorption of concomitantly administered oral drugs. This study investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d450692aa87cde9ce9596440f35eb3b
https://doi.org/10.1177/0091270010389471
https://doi.org/10.1177/0091270010389471
Publikováno v:
The Journal of Clinical Pharmacology. 50:886-894
The once-daily human glucagon-like peptide-1 (GLP-1) analog, liraglutide, was recently shown to provide improved glycemic control in subjects with type 2 diabetes (T2D) compared with exenatide. The aim of this work is to estimate the population pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6481195c4c30cbb785b696a5eb50ab5
https://doi.org/10.1177/0091270009354996
https://doi.org/10.1177/0091270009354996
Publikováno v:
Journal of clinical pharmacology. 55(12)
Insulin degludec/liraglutide (IDegLira) is a novel fixed-ratio combination of the basal insulin insulin degludec (IDeg) and liraglutide, a glucagon-like peptide-1 analog. The pharmacokinetics (PK) and pharmacodynamics of IDegLira were assessed versus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3fdea82f0cbd6843b9df2b123162092
https://pubmed.ncbi.nlm.nih.gov/25998481
https://pubmed.ncbi.nlm.nih.gov/25998481
Publikováno v:
Clinical Pharmacokinetics
Background and Objective The safety, tolerability, and pharmacokinetics of the once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide have been evaluated in pediatric patients aged greater than 10 years with type 2 diabetes (T2D). In thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bda57f82d22091ab59856ad6604e990
https://pubmed.ncbi.nlm.nih.gov/25603819
https://pubmed.ncbi.nlm.nih.gov/25603819
Publikováno v:
Clinical Therapeutics. 24:530-539
Objective: The purpose of this study was to compare the pharmacokinetics and pharmacodynamics of the premixed insulin analogue biphasic insulin aspart (BIAsp 30) with the equivalent premixed biphasic human insulin (BHI 30), administered twice daily,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9cbc49f97a2a6b1190c240991e95434
https://doi.org/10.1016/s0149-2918(02)85129-3
https://doi.org/10.1016/s0149-2918(02)85129-3